Turnstone Biologics acquires Myst Therapeutics

By The Science Advisory Board staff writers

January 20, 2021 -- Biotechnology company Turnstone Biologics has acquired Myst Therapeutics, a developer of a novel cell therapy platform.

The acquisition adds a pipeline of proprietary tumor-infiltrating lymphocyte (TIL) technology and programs to Turnstone's portfolio of oncolytic virus candidates, several of which are expected to enter the clinic in 2021. TIL utilizes populations of T cells that are isolated from a patient's own tumor and are expanded and stimulated before being readministered to the patient.

The terms of the deal were not disclosed. Myst CEO TJ Langer will become Turnstone's senior vice president of cell therapy development and external innovation.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.